Level of Evidence for Therapeutic Drug Monitoring of Ceftriaxone

被引:4
|
作者
Dailly, Eric [1 ,2 ]
Verdier, Marie-Clemence [3 ]
Deslandes, Guillaume [1 ]
Bouquie, Regis [1 ,2 ]
Tribut, Olivier [3 ]
Bentue-Ferrer, Daniele [3 ]
机构
[1] CHU Nantes, Serv Pharmacol Clin, F-44035 Nantes 01, France
[2] Univ Nantes, Fac Med Pharm, EA Biostat Pharmacoepidemiol & Mesures Subject Sa, Nantes, France
[3] CHU Pontchaillou, Lab Pharmacol Biol, Rennes, France
来源
THERAPIE | 2012年 / 67卷 / 02期
关键词
therapeutic drug monitoring; ceftriaxone; BROAD-SPECTRUM CEPHALOSPORINS; BETA-LACTAM ANTIBIOTICS; PHARMACODYNAMIC CONSIDERATIONS; STREPTOCOCCUS-PNEUMONIAE; BILIARY PSEUDOLITHIASIS; LIVER INSUFFICIENCY; ACQUIRED PNEUMONIA; PROTEIN-BINDING; RENAL-FAILURE; PHARMACOKINETICS;
D O I
10.2515/therapie/2012018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Level of Evidence for Therapeutic Drug Monitoring of Ceftriaxone. Ceftriaxone is a third generation cephalosporin with an original pharmacokinetics based on a long elimination half-life among cephalosporins, a high protein binding and a dual renal and biliary elimination. Also the pharmacokinetic parameters of ceftriaxone are highly variable in clinical situations such as severe renal insufficiency, liver and renal insufficiency, the elderly, the neonates less than 1 week of age and critically ill patients. In these clinical situations associated or not with high minimal inhibitory concentration (MIC) level, the relationship concentration-clinical outcome based on the ratio between trough plasma concentration and MIC can allow a dose adjustment. Consequently, therapeutic drug monitoring (TDM) of ceftriaxone could be possibly useful in these situations, whereas the necessity of TDM has still to be demonstrated to monitor toxicity.
引用
收藏
页码:145 / 149
页数:5
相关论文
共 50 条
  • [1] Level of Evidence for Therapeutic Drug Monitoring of Fluconazole
    Venisse, Nicolas
    Le Guellec, Chantal
    THERAPIE, 2011, 66 (02): : 97 - 101
  • [2] Level of Evidence for Therapeutic Drug Monitoring of Posaconazole
    Lefeuvre, Sandrine
    Jelassi, Mohammed-Larbi
    Benlmouden, Amine
    Berge, Maud
    Le Guellec, Chantal
    Billaud, Eliane M.
    THERAPIE, 2011, 66 (02): : 115 - 122
  • [3] Level of Evidence for Therapeutic Drug Monitoring of Vancomycin
    Jelassi, Mohamed Larbi
    Benlmouden, Amine
    Lefeuvre, Sandrine
    Mainardi, Jean-Luc
    Billaud, Eliane M.
    THERAPIE, 2011, 66 (01): : 29 - 37
  • [4] Level of Evidence for Therapeutic Drug Monitoring of Aminoglycosides
    Venisse, Nicolas
    Boulamery, Audrey
    THERAPIE, 2011, 66 (01): : 39 - 44
  • [5] Level of Evidence for Therapeutic Drug Monitoring of Carboplatin
    Hulin, Anne
    Chatelut, Etienne
    Royer, Bernard
    Le Guellec, Chantal
    THERAPIE, 2010, 65 (03): : 157 - 162
  • [6] Level of Evidence for Therapeutic Drug Monitoring of Itraconazole
    Charles, Marie
    Le Guellec, Chantal
    Richard, Damien
    Libert, Frederic
    THERAPIE, 2011, 66 (02): : 103 - 108
  • [7] Level of evidence for therapeutic drug monitoring of taxanes
    Gerritsen-van Schieveen, Pauline
    Royer, Bernard
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 (04) : 414 - 424
  • [8] Level of Evidence for Therapeutic Drug Monitoring of Teicoplatin
    Boulamery, Audrey
    Venisse, Nicolas
    Le Guellec, Chantal
    THERAPIE, 2011, 66 (01): : 45 - 50
  • [9] Level of Evidence for Therapeutic Drug Monitoring of Everolimus
    Goirand, Francoise
    Royer, Bernard
    Hulin, Anne
    Saint-Marcoux, Franck
    THERAPIE, 2011, 66 (01): : 57 - 61
  • [10] Level of Evidence for Therapeutic Drug Monitoring of Cisplatin
    Hulin, Anne
    Royer, Bernard
    Chatelut, Etienne
    Le Guellec, Chantal
    THERAPIE, 2010, 65 (03): : 151 - 155